(+)-PD 128907 HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H563076

CAS#: 300576-59-4 (HCl)

Description: (+)-PD 128907 is a potent agonist of the dopamine 3 (D3) receptor. (+)-PD 128907 shows selectivity for D3 over D2 and D4 receptors (Kis = 1.2 and 7 µM, respectively). PD 128907 inhibits stimulated pyloric relaxation and spontaneous gastric emptying. PD 128907 holds promise as useful agents for treatment of gastric motility disorders.

Chemical Structure

img
(+)-PD 128907 HCl
CAS# 300576-59-4 (HCl)
Instruction

Theoretical Analysis

Hodoodo Cat#: H563076
Name: (+)-PD 128907 HCl
CAS#: 300576-59-4 (HCl)
Chemical Formula: C14H20ClNO3
Exact Mass: 285.11
Molecular Weight: 285.760
Elemental Analysis: C, 58.84; H, 7.05; Cl, 12.41; N, 4.90; O, 16.80

Price and Availability

Size Price Availability Quantity
5mg USD 290
10mg USD 470
25mg USD 790
Bulk inquiry

Related CAS #: 23594-64-9 (free base)   300576-59-4 (HCl)    

Synonym: (+)-PD 128907 HCl; PD-128907; PD128907; PD128907 hydrochloride; PBPO; PBTO;

IUPAC/Chemical Name: (4aS,10bS)-4-Propyl-3,4a,5,10b-tetrahydro-2H-chromeno[4,3-b][1,4]oxazin-9-ol Hydrochloride

InChi Key: DCFXOTRONMKUJB-KYSPHBLOSA-N

InChi Code: InChI=1S/C14H19NO3.ClH/c1-2-5-15-6-7-17-14-11-8-10(16)3-4-13(11)18-9-12(14)15;/h3-4,8,12,14,16H,2,5-7,9H2,1H3;1H/t12-,14-;/m0./s1

SMILES Code: OC1=CC([C@]2([H])OCCN(CCC)[C@@]2([H])CO3)=C3C=C1.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 285.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kotani M, Enomoto T, Murai T, Nakako T, Iwamura Y, Kiyoshi A, Matsumoto K, Matsumoto A, Ikejiri M, Nakayama T, Ogi Y, Ikeda K. The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets. Behav Brain Res. 2016 May 15;305:212-7. doi: 10.1016/j.bbr.2016.02.031. Epub 2016 Mar 9. PMID: 26970575.


2: Bowery BJ, Razzaque Z, Emms F, Patel S, Freedman S, Bristow L, Kulagowski J, Seabrook GR. Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626. Br J Pharmacol. 1996 Dec;119(7):1491-7. doi: 10.1111/j.1476-5381.1996.tb16063.x. PMID: 8968560; PMCID: PMC1915834.


3: Hall H, Halldin C, Dijkstra D, Wikström H, Wise LD, Pugsley TA, Sokoloff P, Pauli S, Farde L, Sedvall G. Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacology (Berl). 1996 Dec;128(3):240-7. doi: 10.1007/s002130050131. PMID: 8972543.


4: Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, et al. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther. 1995 Dec;275(3):1355-66. PMID: 8531103.


5: Zapata A, Witkin JM, Shippenberg TS. Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. Neuropharmacology. 2001 Sep;41(3):351-9. doi: 10.1016/s0028-3908(01)00069-7. PMID: 11522326.


6: Zapata A, Shippenberg TS. Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels. Neuropharmacology. 2005 Jan;48(1):43-50. doi: 10.1016/j.neuropharm.2004.09.003. PMID: 15617726.


7: Pritchard LM, Logue AD, Hayes S, Welge JA, Xu M, Zhang J, Berger SP, Richtand NM. 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology. 2003 Jan;28(1):100-7. doi: 10.1038/sj.npp.1300018. PMID: 12496945.


8: Bancroft GN, Morgan KA, Flietstra RJ, Levant B. Binding of [3H]PD 128907, a putatively selective ligand for the D3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology. 1998 Apr;18(4):305-16. doi: 10.1016/S0893-133X(97)00162-0. PMID: 9509498.


9: Bristow LJ, Cook GP, Patel S, Curtis N, Mawer I, Kulagowski JJ. Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: role of presynaptic dopamine D2 autoreceptors. Neuropharmacology. 1998 Jun;37(6):793-802. doi: 10.1016/s0028-3908(98)00066-5. PMID: 9707293.


10: Bristow LJ, Cook GP, Gay JC, Kulagowski JJ, Landon L, Murray F, Saywell KL, Young L, Hutson PH. The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology. 1996 Mar;35(3):285-94. doi: 10.1016/0028-3908(96)00179-7. PMID: 8783203.


11: Zhang M, Ballard ME, Unger LV, Haupt A, Gross G, Decker MW, Drescher KU, Rueter LE. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav Brain Res. 2007 Aug 22;182(1):1-11. doi: 10.1016/j.bbr.2007.04.021. Epub 2007 May 1. PMID: 17570538.


12: Whetzel SZ, Shih YH, Georgic LM, Akunne HC, Pugsley TA. Effects of the dopamine D3 antagonist PD 58491 and its interaction with the dopamine D3 agonist PD 128907 on brain dopamine synthesis in rat. J Neurochem. 1997 Dec;69(6):2363-8. doi: 10.1046/j.1471-4159.1997.69062363.x. PMID: 9375667.


13: Richtand NM, Welge JA, Levant B, Logue AD, Hayes S, Pritchard LM, Geracioti TD, Coolen LM, Berger SP. Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration. Neuropsychopharmacology. 2003 Aug;28(8):1422-32. doi: 10.1038/sj.npp.1300182. Epub 2003 Apr 16. PMID: 12700693.


14: Huang M, He W, Kiss B, Farkas B, Adham N, Meltzer HY. The Role of Dopamine D3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens. J Pharmacol Exp Ther. 2019 Nov;371(2):517-525. doi: 10.1124/jpet.119.259879. Epub 2019 Sep 11. PMID: 31511365.


15: Kortekaas R, Maguire RP, Cremers TI, Dijkstra D, van Waarde A, Leenders KL. In vivo binding behavior of dopamine receptor agonist (+)-PD 128907 and implications for the "ceiling effect" in endogenous competition studies with [(11)C]raclopride-a positron emission tomography study in Macaca mulatta. J Cereb Blood Flow Metab. 2004 May;24(5):531-5. doi: 10.1097/00004647-200405000-00007. PMID: 15129185.


16: Hillefors M, von Euler M, Hedlund PB, von Euler G. Prominent binding of the dopamine D3 agonist [3H]PD 128907 in the caudate-putamen of the adult rat. Brain Res. 1999 Mar 20;822(1-2):126-31. doi: 10.1016/s0006-8993(99)01138-5. PMID: 10082890.


17: Kleven MS, Koek W. Dopamine D2 receptors play a role in the (-)-apomorphine- like discriminative stimulus effects of (+)-PD 128907. Eur J Pharmacol. 1997 Feb 19;321(1):1-4. doi: 10.1016/s0014-2999(97)00002-2. PMID: 9083778.


18: van Vliet LA, Rodenhuis N, Dijkstra D, Wikström H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Sundell S, Lundmark M. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). J Med Chem. 2000 Jul 27;43(15):2871-82. doi: 10.1021/jm0000113. PMID: 10956195.


19: Akunne HC, Towers P, Ellis GJ, Dijkstra D, Wikström H, Heffner TG, Wise LD, Pugsley TA. Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci. 1995;57(15):1401-10. doi: 10.1016/0024-3205(95)02102-o. PMID: 7674830.


20: Fukunaga Y, Uchida T, Ito Y, Matsumoto K, Katsuki T. Ru(CO)-salen-catalyzed synthesis of enantiopure aziridinyl ketones and formal asymmetric synthesis of (+)-PD 128907. Org Lett. 2012 Sep 7;14(17):4658-61. doi: 10.1021/ol302095r. Epub 2012 Aug 28. PMID: 22928558.